Department of Neonatal Medicine, Connecticut Children's Medical Center, Hartford, CT, USA.
Department of Pediatrics, University of Connecticut Health Center, Farmington, CT, USA.
Stem Cell Res Ther. 2024 Mar 14;15(1):80. doi: 10.1186/s13287-024-03687-3.
Despite advances in neonatal care, the incidence of Bronchopulmonary Dysplasia (BPD) remains high among preterm infants. Human induced pluripotent stem cells (hiPSCs) have shown promise in repairing injury in animal BPD models. Evidence suggests they exert their effects via paracrine mechanisms. We aim herein to assess the effectiveness of extracellular vesicles (EVs) derived from hiPSCs and their alveolar progenies (diPSCs) in attenuating hyperoxic injury in a preterm lung explant model.
Murine lung lobes were harvested on embryonic day 17.5 and maintained in air-liquid interface. Following exposure to 95% O for 24 h, media was supplemented with 5 × 10 particles/mL of EVs isolated from hiPSCs or diPSCs by size-exclusion chromatography. On day 3, explants were assessed using Hematoxylin-Eosin staining with mean linear intercept (MLI) measurements, immunohistochemistry, VEGFa and antioxidant gene expression. Statistical analysis was conducted using one-way ANOVA and Multiple Comparison Test. EV proteomic profiling was performed, and annotations focused on alveolarization and angiogenesis signaling pathways, as well as anti-inflammatory, anti-oxidant, and regenerative pathways.
Exposure of fetal lung explants to hyperoxia induced airspace enlargement, increased MLI, upregulation of anti-oxidants Prdx5 and Nfe2l2 with decreased VEGFa expression. Treatment with hiPSC-EVs improved parenchymal histologic changes. No overt changes in vasculature structure were observed on immunohistochemistry in our in vitro model. However, VEGFa and anti-oxidant genes were upregulated with diPSC-EVs, suggesting a pro-angiogenic and cytoprotective potential. EV proteomic analysis provided new insights in regard to potential pathways influencing lung regeneration.
This proof-of-concept in vitro study reveals a potential role for hiPSC- and diPSC-EVs in attenuating lung changes associated with prematurity and oxygen exposure. Our findings pave the way for a novel cell free approach to prevent and/or treat BPD, and ultimately reduce the global burden of the disease.
尽管新生儿护理技术取得了进步,但早产儿支气管肺发育不良(BPD)的发病率仍然很高。人诱导多能干细胞(hiPSCs)在修复动物 BPD 模型中的损伤方面显示出了前景。有证据表明,它们通过旁分泌机制发挥作用。我们旨在评估源自 hiPSCs 及其肺泡祖细胞(diPSCs)的细胞外囊泡(EVs)在减轻早产肺外植体模型中氧中毒损伤的效果。
在胚胎第 17.5 天收获鼠肺叶,并在气液界面中培养。在暴露于 95%氧气 24 小时后,通过大小排阻色谱法将 5×10 个 EVs 分离物添加到 hiPSCs 或 diPSCs 衍生的培养基中。在第 3 天,通过苏木精-伊红染色和平均线性截距(MLI)测量、免疫组织化学、VEGFa 和抗氧化基因表达来评估外植体。使用单因素方差分析和多重比较检验进行统计分析。进行了 EV 蛋白质组学分析,并对肺泡化和血管生成信号通路以及抗炎、抗氧化和再生途径进行了注释。
将胎儿肺外植体暴露于高氧中会导致气腔扩大、MLI 增加、抗氧化剂 Prdx5 和 Nfe2l2 上调以及 VEGFa 表达下调。用 hiPSC-EVs 处理可改善实质组织学变化。在我们的体外模型中,免疫组织化学未观察到血管结构的明显变化。然而,用 diPSC-EVs 处理可上调 VEGFa 和抗氧化基因,提示其具有促血管生成和细胞保护作用。EV 蛋白质组学分析为影响肺再生的潜在途径提供了新的见解。
这项体外概念验证研究揭示了 hiPSC-和 diPSC-EVs 在减轻与早产和氧气暴露相关的肺变化方面的潜在作用。我们的研究结果为预防和/或治疗 BPD 的新型无细胞方法铺平了道路,并最终减轻了该病的全球负担。